These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35045694)

  • 61. MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.
    Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Rivera Ballesteros O; Muvva JR; ; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren HG; Aleman S; Sandberg JK
    Mol Med; 2022 May; 28(1):54. PubMed ID: 35562666
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination.
    Stankov MV; Cossmann A; Bonifacius A; Dopfer-Jablonka A; Ramos GM; Gödecke N; Scharff AZ; Happle C; Boeck AL; Tran AT; Pink I; Hoeper MM; Blasczyk R; Winkler MS; Nehlmeier I; Kempf A; Hofmann-Winkler H; Hoffmann M; Eiz-Vesper B; Pöhlmann S; Behrens GMN
    Clin Infect Dis; 2021 Dec; 73(11):2000-2008. PubMed ID: 34134134
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
    Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
    JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
    [TBL] [Abstract][Full Text] [Related]  

  • 65. B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e1-1024.e6. PubMed ID: 35259531
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
    Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
    Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

  • 70. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
    Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
    Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
    Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
    Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
    Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
    Front Immunol; 2022; 13():856657. PubMed ID: 35401503
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
    Caocci G; Mulas O; Mantovani D; Costa A; Galizia A; Barabino L; Greco M; Murru R; La Nasa G
    Ann Hematol; 2022 Apr; 101(4):929-931. PubMed ID: 34302519
    [No Abstract]   [Full Text] [Related]  

  • 76. Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination.
    Dulovic A; Strengert M; Ramos GM; Becker M; Griesbaum J; Junker D; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    Emerg Infect Dis; 2022 Apr; 28(4):743-750. PubMed ID: 35203113
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.
    Lyski ZL; Kim MS; Xthona Lee D; Raué HP; Raghunathan V; Griffin J; Ryan D; Brunton AE; Curlin ME; Slifka MK; Messer WB; Spurgeon SE
    Blood Adv; 2022 Feb; 6(4):1207-1211. PubMed ID: 34872103
    [No Abstract]   [Full Text] [Related]  

  • 79. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
    Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
    Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.